With another calendar year just weeks away, forecasting experts are speculating on what the pharmaceutical pipeline will deliver in 2005. Lee Vermeulen, R.Ph., M.S., along with his colleagues at the University of Wisconsin Hospital and Clinics, believes the action in 2005 will be in biotech and that pharmacists should not ignore the agents currently being reviewed by the Food & Drug Administration.
FDA’s Recent Exemptions: What Do They Mean as We Finalize DSCSA Implementation?
October 31st 2024Kala Shankle, Vice President of Regulatory Affairs with the Healthcare Distribution Alliance, and Ilisa Bernstein, President of Bernstein Rx Solutions, LLC, discussed recent developments regarding the Drug Supply Chain Security Act.